Ryuji Ueno, M.D., Ph.D., Founder, Chairman and Chief Executive Officer
of Sucampo Pharmaceuticals, Inc., Rings the NASDAQ Opening Bell
October 22, 2007 - Times Square, NYC
About this Marketsite Event:
Ryuji Ueno, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc.., rings the Opening Bell.
Headquartered in Bethesda, Maryland, Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals' first product, AMITIZA(r) (lubiprostone), received marketing approval from the FDA in January 2006.
To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Press Inquiries Only:
Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at
jolene.libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission.
Other Photography Inquiries:
For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at
rob.tannenbaum@nasdaq.com.
© Copyright 2007, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.
